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Abstract: Hepatitis B (HBV) is a pathogen virus with transmission mechanisms that include contact
with the infected blood or bodily fluids of the infected organism. Nowadays, healthcare workers are
one of the most exposed groups to HBV. Conventionally, completing a vaccine series dosage with
Engerix B® lowers this risk by providing workers with immunity to the virus. However, through the
years, we have encountered nonresponsive health personnel to the Engerix B® vaccine; hence, the
Occupational Health Service of Poniente Hospital studied the Fendrix® adjuvanted vaccine as an
alternative vaccine to develop immunological responses in healthcare workers who do not respond
to vaccination with Engerix B®. In our study, we employed a vaccination schedule with the Fendrix®
vaccine, performing serology tests on the cases after the application of each dose. The results obtained
showed humoral immunity in 92.3% of the cases, with a remarkable increase in antibody titer after
the first doses. These encouraging results support the future inclusion of this vaccine as one possible
alternative for the immunization to HBV for healthcare workers nonresponsive to Engerix B®.
Keywords: Hepatitis B; vaccination; fendrix; healthcare workers; occupational health
1. Introduction
Vaccines are the primary prevention tool against various biological agents through the
development of humoral immunity. This humoral immunity, or immunological memory, is
achieved by exposing an individual to the pathogen by one of the following mechanisms:
direct exposure, by the inoculation of a less virulent strain of the microbe (attenuated
vaccine) or indirect exposure, by the inoculation of antigenic fragments of the pathogen,
which are normally expressed in the organism during the regular infection process (inacti-
vated vaccine) [1].
Although both types of vaccination have a high rate of efficiency, inactivated hepatitis
B vaccine has been found to have a lower immunization rate following complete dosage
guidelines than other vaccines routinely administered to the general population and health
personnel. In this way, although many risk factors are considered for a vaccine to be
effective or not, there is still much to discover and specify [2], but in the meantime, we
must try to develop immunity in all people who have not yet generated immune protection
through the usual vaccines.
The Spanish National Healthcare System provides a wide vaccination coverage which
employs both attenuated and inactivated vaccines. The annual vaccination schedule is
targeted at the at-risk population groups: children and the elderly [3,4].
The Spanish Healthcare System also recommends the vaccination of other at-risk
population groups, either due to previous pathologies such as immunosuppression, asple-
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nia, and/or transplanted patients [5,6], or due to a high exposure risk, such as essential
healthcare workers [7].
In a previous function performed by our research group, the efficiency and importance
of the correct vaccination of healthcare workers has been studied, since this group is
constantly exposed to multiple biological risks [8]. In said study, the high efficiency
of vaccines administered against measles, rubella, mumps, chickenpox, and hepatitis
B in nonimmunized health personnel was proven. However, the vaccine administered
against the hepatitis B virus (HBV) presents the lowest efficiency of the set—84.8% of
postvaccination immunity when correctly following the vaccination series schedule [8,9].
The Engerix B® vaccine, regularly used for HBV immunization, consists of a 1 mL
solution of an HBV surface pathogen (standard dose 20 mcg/mL). The schedule for this
vaccine consists of three doses: an initial dose, a second dose after 1 month, and a third
dose after 6 months [10,11]. If the postvaccination serology test performed at the seventh
month after the first dose results in a reading of anti-HBs < 10 mIU/mL, a new second full
dose schedule is proposed to be repeated, and if a low titer of anti-HBs is observed, the
worker is considered nonresponsive and no further vaccination procedure is performed.
The adjuvanted vaccine Fendrix® is of restricted use, with a high immunological
capacity, and its target population are renal insufficiency patients. Acting through the
antigen release system, this vaccine can increase the availability of antigen in antigen-
presenting cells. A delay in antigenic clearance and an increase in antigen response is
achieved in specific physiological location (through aluminum salts), as well as through the
use of immune-enhancers such as 3-O-desacyl-4-monophosphoryl lipid A (MPL), which
directly activate cell receptors and induce the release of cytokines [12].
Currently, this vaccine is not included in any vaccination program for health personnel;
however, the Occupational Health Service of Poniente Hospital was authorized by the
hospital pharmacy for its application for healthcare workers nonresponsive to Engerix B®.
The recommended number of doses is 4: an initial dose and after 1, 2 and 6 months after
receiving the vaccination [13,14].
The objective of this study is to demonstrate the high effectiveness of the Fendrix®
vaccine, and to provide the required evidence for its future inclusion in the vaccination
plans of the National Health Authorities in Spain for healthcare workers.
2. Material and Methods
2.1. Study Description
A prospective study to determine the effectiveness of the Fendrix® vaccine was
performed on healthcare providers nonresponsive to Engerix B®.
2.2. Participants
In total, 26 healthcare workers were selected by the Occupational Health Service of
Poniente Hospital in southeastern Spain (Almeria, Spain) in the 2011–2020 period. None of
the initially recruited workers abandoned the study.
The inclusion criterion for all health personnel was that after the application of 2 com-
plete vaccination schedules with Engerix B®, they did not develop immunity against HBV,
objectively demonstrated by the necessary serology tests (to detect possible antibodies
against HBV). The exclusion criteria included those healthcare workers with prior HBV
immunity or those without immunity but that had not complied with the Engerix B®
vaccination stipulations. In this study, only one group was assigned (there is not a control
group). There was no randomization or masking.
All participants were informed about the study and signed the appropriate informed
consent form.
2.3. Engerix B®
Engerix B® is the vaccine of choice to develop immunity against HBV. The vaccine is
comprised of a surface antigen of the viral shell at a concentration of 20 µg/mL in a solution
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containing sodium chloride, sodium phosphate and water, preserved at a temperature
between 2 and 8 ◦C.
The doses applied to the hospital healthcare workers prior to their inclusion in this
research were those recommended by the Spanish Agency of Medicines and Medical
Devices (AEMPS), with inoculation at months 0, 1 and 6 [10].
2.4. Fendrix®
Fendrix® is an adjuvanted vaccine with higher immunogenic capacity compared to
other traditionally employed vaccines against Hepatitis B. This vaccine was to be used only
in patients with renal insufficiency, helping them develop better protection against HBV.
For this, in addition to the surface antigen, Fendrix® contains two compounds the adjuvant
molecule MPL in conjunction with the surface antigen of HBV dissolved in aluminum
phosphate. The recommended preservation temperature range is between 2 and 8 ◦C.
The doses applied also followed the indications by the AEMPS, with inoculation at
months 0, 1, 2, and 6 [13].
2.5. Procedure
Healthcare providers who did not develop immunity to HBV after completing the
3-dose vaccination schedule with Engerix B® at months 0, 1, and 6 (anti-HBs level < 10
after the vaccination) were informed about the possibility to develop immunity against
Hepatitis B by commencing a vaccination schedule with Fendrix®.
Participants were informed about the procedure being outside of the recommendation
by the AEMPS and about the possible contraindications and adverse effects of the Fendrix®
vaccine.
Those health personnel who consented to participate in this study were vaccinated
following the previously mentioned indications, with a vaccination schedule consisting of
four doses applied at months 0, 1, 2 and 6. Thirty days after administering each dose, a
serology test was performed with the objective of determining at which point each individ-
ual developed immunity against HBV. Due to the high cost of Fendrix®, after demonstrably
achieving immunity against hepatitis B, each participant was given the option to not com-
plete the original vaccination schedule. For those participants who after the completion of
the full vaccination schedule the result of the serology test was nonconclusive, an additional
dose of Fendrix® was offered together with additional serology testing. (Scheme 1).




Scheme 1. Fendrix® vaccine vaccination protocol. 
2.6. Statistical Analysis 
A database was created with the variables studied in this article and statistical data 
analysis of said data was performed using IBM SPSS version 22.0, 2013 [15]. 
First, a descriptive analysis of continuous variables was performed, expressed as av-
erages and standard deviations. Categorial values were expressed alongside their respec-
tive frequencies and percentages. Afterwards, in order to determine whether the continu-
ous variables fit a normal distribution or not, a Kolmogorov–Smirnov test was performed. 
For the comparison of the variables following a normal distribution, Student’s t-distribu-
tion was employed, whereas non-normally distributed variables were compared with the 
Mann–Whitney U test. In the bivariate analysis of qualitative variables, the chi-squared 
test (χ2) was employed with p < 0.05. 
2.7. Ethical Considerations 
The approval for the application of the Fendrix® vaccine outside of the common rec-
ommended usage by the AEMPS was provided by the hospital pharmacy, with the re-
quirement of informing the participants of the study about possible contraindications and 
adverse effects. With this approach, signing an informed consent form was required prior 
to the participation in this study for the application of the Fendrix® vaccine. 
This study was performed following Good Clinical Practice Guidelines, and it con-
formed to the Declaration of Helsinki, observing all ethical requirements for medical re-
search on human beings. This study also followed the principles and conventions of the 
Council of Europe related to human rights and biomedicine, and all stipulations present 
in the Spanish law regarding bioethics. 
Patient voluntary consent was conditio sine qua non in all cases, and all participants 
could retract their consent at any time and thus abandon the study. 
Each worker was assigned an ID to provide them with anonymity. This study was 
approved by the provincial ethics and research committee number 12 on 18 December 
2019 (research code: PI_19_41). 
3. Results 
A total of 26 healthcare workers participated in the study. Participant average age 
was 46.12 ± 8.07 years, and 57.7% were women. Regarding dosing, 50% of the workers 
were inoculated with one dose (n = 13), 7.7% were inoculated with two doses (n = 2), 26.9% 
were inoculated with three doses (n = 7), and the remaining 15.4% were inoculated with 
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2.6. Statistical Analysis
A database was created with the variables studied in this article and statistical data
analysis of said data was performed using IBM SPSS version 22.0, 2013 [15].
First, a descriptive analysis of continuous variables was performed, expressed as
averages and standard deviations. Categorial values were expressed alongside their
respective frequencies and percentages. Afterwards, in order to determine whether the
continuous variables fit a normal distribution or not, a Kolmogorov–Smirnov test was
performed. For the comparison of the variables following a normal distribution, Student’s
t-distribution was employed, whereas non-normally distributed variables were compared
with the Mann–Whitney U test. In the bivariate analysis of qualitative variables, the
chi-squared test (χ2) was employed with p < 0.05.
2.7. Ethical Considerations
The approval for the application of the Fendrix® vaccine outside of the common
recommended usage by the AEMPS was provided by the hospital pharmacy, with the
requirement of informing the participants of the study about possible contraindications
and adverse effects. With this approach, signing an informed consent form was required
prior to the participation in this study for the application of the Fendrix® vaccine.
This study was performed following Good Clinical Practice Guidelines, and it con-
formed to the Declaration of Helsinki, observing all ethical requirements for medical
research on human beings. This study also followed the principles and conventions of the
Council of Europe related to human rights and biomedicine, and all stipulations present in
the Spanish law regarding bioethics.
Patient voluntary consent was conditio sine qua non in all cases, and all participants
could retract their consent at any time and thus abandon the study.
Each worker was assigned an ID to provide them with anonymity. This study was
approved by the provincial ethics and research committee number 12 on 18 December 2019
(research code: PI_19_41).
3. Results
A total of 26 healthcare workers participated in the study. Participant average age
was 46.12 ± 8.07 years, and 57.7% were women. Regarding dosing, 50% of the workers
were inoculated with one dose (n = 13), 7.7% were inoculated with two doses (n = 2), 26.9%
were inoculated with three doses (n = 7), and the remaining 15.4% were inoculated with
four doses (n = 4) (Figure 1). The average antibody titer obtained from the participants was
anti-HBs = 325 ± 304.9 mIU/mL, thus achieving immunity in 92.3% of healthcare workers
(n = 24).
Statistically significant differences were found for the development of immunity
against the hepatitis B virus depending on the number of doses employed and the antibody
titer levels produced by the participants (anti-HBs). In this respect, the average number of
doses required for immunity development was found to be 1.92 ± 1.1, with an average anti-
HB level of 351.83 ± 302.14 mIU/mL. The 7.7% of healthcare providers who did not develop
immunity received four doses and presented an anti-HBs titer of 3.1 ± 4.38 mIU/mL
(Table 1).
Table 1. Correlation between immunity, age, and antibody titer (n = 26).
Immunity
Variable Yes No p
Age (years) * 45.58 ± 8.19 52.50 ± 0.71 0.032
anti-HBs ** (mIU/mL) 351.83 ± 302.14 3.10 ± 4.38 0.021
Bivariate analysis of the relationship between immunity with the other variables using Student’s t-distribution *
and Mann–Whitney U test **.
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Furthermore, statistically significant differences were found depending on the age
of the vaccinated workers. The average age of workers who developed immunity was
45.58 ± 8.19 years, whereas the average age of workers who did not develop immunity
was 52.5 ± 0.71 years (Table 1).
No statistically significant differences between the gender of the participants and
the rest of the analyzed variables—immunity development, age, number of doses, and
antibody titer—were found (Table 2).
Table 2. Correlation between gender and anti-HBs titer with the remaining variables (n = 26).
Gender pVariable Male Female
Age (years) * 44.73 ± 9.06 47.13 ± 7.43 0.464
No. of doses ** 2.18 ± 1.08 2.00 ± 1.31 0.646
anti-HBs ** (mIU/mL) 435.04 ± 324.45 244.31 ± 272.64 0.164
Yes 11 13
Immunity ***
No 0 2 0.207
Variable N. Doses p
anti-HBs **** (mIU/mL) −0.347 0.083
Bivariate analysis of the relationship between immunity with the other variables using Student’s t-distribution *,
Mann–Whitney U test **, chi-squared test (χ2) *** and Rho-Spearman ****.
Neither could a statistically significant correlation between the antibody titer and the
number of doses inoculated be found, or with the age of the healthcare workers. However,
in the case of the antibody titer and the number of doses given, a weak, negative correlation
was found (p = 0.083) (Table 2).
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4. Discussion
The present study is part of an ambitious larger project which advocates the extension
of the prescriptive usage of the Fendrix® vaccine in health personnel nonresponsive to
Engerix B® vaccination. It must be mentioned that this group deals with high work-related
biological risks. The type of possible accidents with biological risk include stabbing with
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sharp medical instrumentation and contact with potentially contaminated bodily fluids,
amongst others. These work-related risks are prevalent and typically underreported [16],
hence the exposure risk to hepatitis B contagion by contact with contaminated sources
is potentially elevated, giving rise to situations in which appropriate chemoprophylaxis
procedures cannot be undertaken [17]. Thus, providing healthcare providers with im-
munity against HBV is of the utmost importance. It must also be noted that HBV is the
pathogen with the highest seroconversion capacity among the microbiological work-related
biological risk accidents, with a seroconversion capacity of 20–30% in exposure cases in
its positive E antigen (HBeAc+) replicative form [18]. By increasing the personnel with
immunity against HBV, the negative effects of hepatitis B on healthcare workers could be
prevented in most cases [19], alongside the reduction in the direct and indirect costs on the
National Healthcare System resulting from newly infected workers [20].
Internationally, several studies endorse the inclusion of the Fendrix® vaccine outside
its common indications and its inclusion in the immunization schedule to develop im-
munity in people nonresponsive to the currently used HBV vaccines. These studies have
found an efficacy of the Fendrix® vaccine in over 85% of the patients, results similar to
those found in this research [21,22].
In Spain, a research study similar to this one can be found in the literature that sought
to demonstrate the efficacy of the adjuvanted vaccine and support its inclusion in the
vaccine calendar of nonresponsive health personnel [23]. In said article, the same popula-
tion group was targeted for the testing of the Fendrix® vaccine, with similar vaccination
schedules and conditions to our own. This investigation demonstrated high efficacy (>90%)
and high efficiency, with serological immunization in over 50% of healthcare workers after
the inoculation with the first dose. In our project, these results have been complemented
with the description of their prevalence, and alongside this we have established a relevant
relation between the number of Fendrix® doses of inoculation and immunity development.
This can be due to the elevated response potential adjuvanted vaccines cause, which favor
greater local inflammatory reaction and activating the immunological response faster [24].
A significant correlation between the number of generated antibodies and the number
of doses given cannot be demonstrated with our data. This correlation has, however,
been found in other studies in which Fendrix® was used, with up to a 9-fold increase in
antibody count compared to a complete Engerix B® vaccination schedule [25,26]. One
possible reason our investigation could not determine this correlation might be the number
of cases evaluated. Increasing the population studied, either by the inclusion of new
participants within our health center or from patients coming from other health facilities
in a future project, might allow us to find a definitive correlation between these two
variables. If this were the result, it would further help the case for the correlation between
the cause of greater inflammatory reactions to adjuvant vaccines and the greater-scale
immunological response [26].
On another note, this study demonstrates that vaccine efficacy is higher in younger
patients, with decreased immunity development in patients older than 50 years. These
results are in line with other previous research works on the general efficacy of vaccines [27]
and point to a better capacity and higher activity of the immunological system in younger
people in the detection of potentially noxious pathogens as the main reason for this. Thus,
the immunological response of the organism decreases with age, which in turn causes a
lower immunological reaction against vaccines. Indeed, senectitude is a risk factor that
predisposes one to contagious infection due to a “physiological immunodepression”, which
supports the data found on the lower efficacy of vaccines in this population group [28].
Other research studies at a Spanish level have found differences in the efficacy of hep-
atitis B vaccines according to gender, with lower efficacy in male healthcare providers [29].
While our article could not replicate these results, since healthcare workers in our health
center are women by a large majority, there is a similar number of male and female workers
in our study—11 male and 15 female workers—which could be an indication of a higher
proportion of nonresponsive male workers to Engerix B® vaccination. Again, this limitation
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in the number of study subjects may have prevented us from replicating the results found
by the aforementioned work.
Within the limitations of this research, sample size must be again mentioned. With a
higher number of test subjects, some or all of the previously discussed correlations found
in other research works might have been reproduced. Increasing sample size would hence
be the logical solution to this issue; however, the requirements and specifics necessary to be
considered as a candidate to participate in this research make it difficult to include a higher
number of test subjects at this moment. In the future, a collaboration with other health
centers at the national level could help overcome this limitation. Another limitation was
that the study does not have a control arm with additional doses of Engerix B® or similar
vaccine to compare with the results of Fendrix®.
The findings discussed herein could support the argument for the inclusion of higher
efficacy vaccines such as Fendrix® for healthcare workers exposed to the HBV pathogen
and who were nonresponsive to the regular, standardized vaccination schedule. Several
research groups explain the possibility of extending the standardized use of highly effective
vaccines, such as Fendrix® or HBVAXPRO®, for this type of target population who are
highly exposed to contact with HBV, offering them protection and a lot of advantages to
the society [30]. Increasing the immunity against this virus amongst the target population
could reduce the risk faced regarding future work-related biological accidents. This would
result in both reduced negative health effects for health personnel and a reduced economic
cost since the target population is small. This would result in a positive outcome regarding
socio-economic costs in the healthcare system and the psychological health of healthcare
workers.
5. Conclusions
The use of adjuvanted vaccines such as Fendrix® allows the development of immunity
against pathogens, such as hepatitis B virus, against which standard vaccines have not
resulted in serological protection for the inoculated patients. With its inclusion of said
vaccine on the standard immunization schedule of nonresponsive healthcare workers,
higher protection for this population group could be provided against hepatitis B, as they
are exposed to constant risk of contagions with these pathogens in the form of injuries with
contaminated sharp medical instrumentation and splatter from bodily fluids.
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